|Bid||0.6430 x 1800|
|Ask||0.6675 x 1200|
|Day's Range||0.6321 - 0.7190|
|52 Week Range||0.2050 - 10.8000|
|Beta (5Y Monthly)||3.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Advaxis, Inc. (NASDAQ: ADXS ) has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days. Investors have viewed the developments ...
Advaxis stock is flying high Monday on news concerning a Phase1/2 study of ADXS-PSA.Source: Shutterstock ADXS-PSA is Advaxis' (NASDAQ:ADXS) Listeria monocytogenes-based immunotherapies. The drug is being evaluated for use on its own, as well as with Merck's (NYSE:MRK) anti-PD-1 therapy.The study of ADXS-PSA is broken up into two separate parts. The first is Part A, which focuses on the drug's effectiveness when used on its own. The second is Part B, which tests how it does alongside MRK's drug.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe important biotech news from Advaxis today has to do with the Part B portion of the study. New from this study shows that it is performing well when it comes to tolerability. There have been no major adverse events or additive toxicity.Another strong point from the Part B section of the study includes response from T-cell's to ADXS-PSA. There was a reaction from T-cells in 75% of subjects. It's also worth noting that antigen spreading was seen in 85% of subjects.More data from the ADXS-PSA study also finds patients taking part in the study to have a long survival rate. At the cutoff time for the data in this report, the median survival rate for patients in te study was 21.1 months. * The Elite 8 Stocks to Buy for Massive Outperformance Based on the prolonged survival data and strong safety profile to date, we believe that continued clinical development of ADXS-PSA in combination with KEYTRUDA® is warranted and represents a potentially significant opportunity for Advaxis," Kenneth Berlin, President and CEO of Advaxis, said in a statement.ADXS stock was up 16% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Advaxis Stock Is Soaring Today appeared first on InvestorPlace.
Biotech stocks have managed to end the quarter in the green, supported in part by the broader market sentiment and some company-specific catalytic events. Curis, Inc. (NASDAQ: CRIS ) and PhaseBio Pharmaceuticals ...
On a per-share basis, the Princeton, New Jersey-based company said it had profit of 18 cents. Earnings, adjusted for non-recurring gains, came to 15 cents per share. The biotechnology company posted revenue ...
Advaxis (ADXS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Advaxis, Inc. (NASDAQ:ADXS), which has zero-debt onRead More...